Asia Pacific Advanced Therapy Medicinal Products Market Size & Outlook
Asia Pacific advanced therapy medicinal products market, 2018-2030 (US$M)
Related Markets
Asia Pacific advanced therapy medicinal products market highlights
- The Asia Pacific advanced therapy medicinal products market generated a revenue of USD 2,040.4 million in 2023.
- The market is expected to grow at a CAGR of -100% from 2024 to 2030.
- In terms of segment, gene therapy was the largest revenue generating product in 2023.
Asia Pacific data book summary
| Market revenue in 2023 | USD 2,040.4 million |
| Market revenue in 2030 | USD 0.0 million |
| Growth rate | -100% (CAGR from 2023 to 2030) |
| Largest segment | Gene therapy |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Gene Therapy, Cell Therapy, Tissue Engineered, Others (Combined ATMPs, for example biodegradable matric or scaffold) |
| Key market players worldwide | Bluebird bio Inc, Novartis AG ADR, UniQure NV, Gilead Sciences Inc, JCR Pharmaceuticals Co Ltd, Vericel Corp, Organogenesis Holdings Inc Class A, Spark Therapeutics, Celgene, Kolon Industries, Medipost, Pharmicell |
Other key industry trends
- In terms of revenue, Asia Pacific region accounted for 28.3% of the global advanced therapy medicinal products market in 2023.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Advanced Therapy Medicinal Products Market Scope
Advanced Therapy Medicinal Products Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Asia Pacific advanced therapy medicinal products market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to advanced therapy medicinal products market will help companies and investors design strategic landscapes.
Gene therapy was the largest segment with a revenue share of 52% in 2023. Horizon Databook has segmented the Asia Pacific advanced therapy medicinal products market based on gene therapy, cell therapy, tissue engineered, others (combined atmps, for example biodegradable matric or scaffold) covering the revenue growth of each sub-segment from 2018 to 2030.
Over the recent past, Asia Pacific’s ATMP market, with Japan, China, and South Korea at the forefront, has been gaining momentum globally. Biotech companies from other regions are focusing on development of innovative therapies by expanding their technologies and presence in Asian Pacific.
In March 2019, Merck entered in a strategic alliance with China’s GenScript for gene and cell therapy manufacturing. Under this collaboration, Merck would offer its manufacturing services to GenScript.
Reasons to subscribe to Asia Pacific advanced therapy medicinal products market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Asia Pacific advanced therapy medicinal products market databook
-
Our clientele includes a mix of advanced therapy medicinal products market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific advanced therapy medicinal products market , including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific advanced therapy medicinal products market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Asia Pacific advanced therapy medicinal products market size, by country, 2018-2028 (US$M)
Asia Pacific Advanced Therapy Medicinal Products Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
